School of Medicine


Showing 1-20 of 25 Results

  • Ranjana Advani

    Ranjana Advani

    Saul A. Rosenberg, MD, Professor of Lymphoma

    Current Research and Scholarly InterestsClinical investigation in Hodgkin's disease, non-Hodgkin's Lymphomas and cutaneous lymphomas. Experimental therapeutics with novel chemotherapy and biologically targeted therapies.

    The research program is highly collaborative with radiation oncology, industry, pathology and dermatology.

  • Ash A. Alizadeh, MD/PhD

    Ash A. Alizadeh, MD/PhD

    Associate Professor of Medicine (Oncology)

    Current Research and Scholarly InterestsMy research is focused on attaining a better understanding of the initiation, maintenance, and progression of tumors, and their response to current therapies toward improving future treatment strategies. In this effort, I employ tools from functional genomics, computational biology, molecular genetics, and mouse models.

    Clinically, I specialize in the care of patients with lymphomas, working on translating our findings in prospective cancer clinical trials.

  • Sean Bendall

    Sean Bendall

    Assistant Professor (Research) of Pathology

    Current Research and Scholarly InterestsOur goal is to understand the mechanisms regulating the development of human systems. Drawing on both pluripotent stem cell biology, hematopoiesis, and immunology, combined with novel high-content single-cell analysis (CyTOF – Mass Cytometry) and imagining (MIBI-Multiplexed Ion Beam Imaging) we are creating templates of ‘normal’ human cellular behavior to both discover novel regulatory events and cell populations as well as understand dysfunctional processes such as cancer.

  • Michael Cleary

    Michael Cleary

    Lindhard Family Professor in Pediatric Cancer Biology and Professor of Pathology

    Current Research and Scholarly InterestsThe role of oncoproteins in cancer and development; molecular and cellular biology of hematologic malignancies; targeted molecular therapies of cancer.

  • Steven Coutre

    Steven Coutre

    Professor of Medicine (Hematology) at the Stanford University Medical Center

    Current Research and Scholarly InterestsMy research integrates clinical care of patients with novel treatments for a variety of hematologic disorders. I see patients with a wide range of problems with a particular focus on chronic lymphocytic leukemia and multiple myeloma. I provide comprehensive consultative services as well as treatment for both the acute and chronic leukemias as well as non-malignant conditions such as clotting disorders and thrombocytopenia.

  • Kara Davis

    Kara Davis

    Assistant Professor of Pediatrics (Hematology/Oncology) at the Lucile Salter Packard Children's Hospital

    Current Research and Scholarly InterestsChildhood cancers can be considered aberrations of normal tissue development. We are interested in understanding childhood cancers through the lens of normal development. Further, individual tumors are composed of heterogeneous cell populations, not all cells being equal in their ability to respond to treatment or to repopulate a tumor. Thus, we take single cell approach to determine populations of clinical relevance.

  • Dean W. Felsher

    Dean W. Felsher

    Professor of Medicine (Oncology) and of Pathology
    On Partial Leave from 03/01/2020 To 08/31/2020

    Current Research and Scholarly InterestsMy laboratory investigates how oncogenes initiate and sustain tumorigenesis. I have developed model systems whereby I can conditionally activate oncogenes in normal human and mouse cells in tissue culture or in specific tissues of transgenic mice. In particular using the tetracycline regulatory system, I have generated a conditional model system for MYC-induced tumors. I have shown that cancers caused by the conditional over-expression of the MYC proto-oncogene regress with its inactivation.

  • Jason Gotlib

    Jason Gotlib

    Professor of Medicine (Hematology) at the Stanford University Medical Center

    Current Research and Scholarly InterestsMy research interests include phase I/II clinical trial evaluation of novel therapies for the following diseases:
    --Myelodysplastic syndromes (MDS)
    --Chronic myelogenous leukemia (CML)
    --Acute myelogenous leukemia (AML)
    --Myeloproliferative disorders (MPDs) including:
    Hypereosinophilic syndrome
    Systemic mastocytosis
    BCR-ABL-negative MPDs

  • Richard Hoppe

    Richard Hoppe

    Henry S. Kaplan-Harry Lebeson Professor of Cancer Biology

    Current Research and Scholarly InterestsIrradiation immunosuppression; total body irradiation;, psychosocial effects of cancer treatment; treatment of lymphoma;, mycosis fungoides.

  • Siddhartha Jaiswal

    Siddhartha Jaiswal

    Assistant Professor of Pathology

    Current Research and Scholarly InterestsWe identified a common disorder of aging called clonal hematopoiesis of indeterminate potential (CHIP). CHIP occurs due to certain somatic mutations in blood stem cells and represents a precursor state for blood cancer, but is also associated with increased risk of cardiovascular disease and death. We hope to understand more about the biology and clinical implications of CHIP using human and model system studies.

  • Ted Jardetzky

    Ted Jardetzky

    Professor of Structural Biology

    Current Research and Scholarly InterestsThe Jardetzky laboratory is studying the structures and mechanisms of macromolecular complexes important in viral pathogenesis, allergic hypersensitivities and the regulation of cellular growth and differentiation, with an interest in uncovering novel conceptual approaches to intervening in disease processes. Ongoing research projects include studies of paramyxovirus and herpesvirus entry mechanisms, IgE-receptor structure and function and TGF-beta ligand signaling pathways.

  • Youn H Kim, MD

    Youn H Kim, MD

    The Joanne and Peter Haas, Jr., Professor for Cutaneous Lymphoma Research and Professor, by courtesy, of Medicine (Oncology) at the Stanford University Medical Center

    Current Research and Scholarly InterestsClinical research in cutaneous lymphomas, especially, mycosis fungoides; studies of prognostic factors, long-term survival results, and effects of therapies. Collaborative research with Departments of Pathology and Oncology in basic mechanisms of cutaneous lymphomas. Clinical trials of new investigative therapies for various dermatologic conditions or clinical trials of known therapies for new indications.

  • Norman J. Lacayo, MD

    Norman J. Lacayo, MD

    Associate Professor of Pediatrics (Hematology and Oncology) at the Lucile Salter Packard Children's Hospital

    Current Research and Scholarly InterestsPediatric Hematology/Oncology, Phase I drug studies for refractory and relapsed leukemia; genomic studies, biologic risk-stratification and treatment of acute myeloid leukemia; prediction or induction response and risk of relapse using phosphoproteomics in childhood AML; novel MRD techniques in childhood ALL.

  • Ronald Levy, MD

    Ronald Levy, MD

    Robert K. and Helen K. Summy Professor in the School of Medicine

    Current Research and Scholarly InterestsClinical Interests: lymphoma. Research Interests: Immunology and molecular biology of lymphoid malignancy; molecular vaccines for cancer.

  • Michael Link

    Michael Link

    Lydia J. Lee Professor in Pediatric Cancer

    Current Research and Scholarly InterestsHematology/Oncology, treatment of sarcomas of bone and soft tissue, biology of acute lymphoblastic leukemias, treatment of non-Hodgkin's lymphoma and Hodgkin's disease.

  • Ravindra Majeti MD, PhD

    Ravindra Majeti MD, PhD

    Professor of Medicine (Hematology)

    Current Research and Scholarly InterestsThe Majeti lab focuses on the molecular/genomic characterization and therapeutic targeting of leukemia stem cells in human hematologic malignancies, particularly acute myeloid leukemia (AML). Our lab uses experimental hematology methods, stem cell assays, genome editing, and bioinformatics to define and investigate drivers of leukemia stem cell behavior. As part of these studies, we have led the development and application of robust xenotransplantation assays for human hematopoietic cells.

  • Beverly S. Mitchell, M.D.

    Beverly S. Mitchell, M.D.

    George E. Becker Professor in Medicine and Professor, by courtesy, of Chemical and Systems Biology

    Current Research and Scholarly InterestsBeverly Mitchell's research relates to the development of new therapies for hematologic malignancies, including leukemias and myelodsyplastic syndromes. She is interested in preclinical proof of principle studies on mechanisms inducing cell death and on metabolic targets involving nucleic acid biosynthesis in malignant cells. She is also interested in the translation of these studies into clinical trials.

  • Yasodha Natkunam, M.D., Ph.D

    Yasodha Natkunam, M.D., Ph.D

    Ronald F. Dorfman, MBBch, FRCPath Professor in Hematopathology

    Current Research and Scholarly InterestsMy research interests focus on the identification and characterization of markers of diagnostic and prognostic importance in hematolymphoid neoplasia.

  • Garry Nolan

    Garry Nolan

    Rachford and Carlota Harris Professor

    Current Research and Scholarly InterestsDr. Nolan's group uses high throughput single cell analysis technology cellular biochemistry to study autoimmunity, cancer, virology (influenza & Ebola), as well as understanding normal immune system function. Using advanced flow cytometric techniques such as Mass Cytometry, MIBI (ion beam imaging), CODEX and computational biology approaches, we focus on understanding disease processes at the single cell level. We have a strong interest in cancer immunotherapy and pathogen-host interactions.

  • Sylvia K. Plevritis, PhD

    Sylvia K. Plevritis, PhD

    Professor of Biomedical Data Science and of Radiology (Integrative Biomedical Imaging Informatics at Stanford)

    Current Research and Scholarly InterestsMy research program focuses on computational modeling of cancer biology and cancer outcomes. My laboratory develops stochastic models of the natural history of cancer based on clinical research data. We estimate population-level outcomes under differing screening and treatment interventions. We also analyze genomic and proteomic cancer data in order to identify molecular networks that are perturbed in cancer initiation and progression and relate these perturbations to patient outcomes.